Erasca's RAS-targeting drug ERAS-0015 showed tumor shrinkage in 40% of pancreatic cancer patients and 62% of non-small cell lung cancer patients, surpassing initial expectations. These findings could drive new developments in targeted oncology treatments for tech professionals focused on biotech advancements. Further trials will be crucial to confirm the drug's efficacy and safety profile.
Read the full article at STAT News
Want to create content about this topic? Use Nemati AI tools to generate articles, social posts, and more.

![[AINews] The Unreasonable Effectiveness of Closing the Loop](/_next/image?url=https%3A%2F%2Fmedia.nemati.ai%2Fmedia%2Fblog%2Fimages%2Farticles%2F600e22851bc7453b.webp&w=3840&q=75)



